Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Maternal serum placental growth factor at 11–13 weeks in chromosomally abnormal pregnancies

10 Mar 2009

Abstract excerpt

OBJECTIVES: To investigate the potential value of maternal serum placental growth factor (PlGF) in first-trimester screening for trisomy 21 and other major chromosomal abnormalities. METHODS: The maternal serum concentration of PlGF at 11 + 0 to 13 + 6 weeks was measured in 609 euploid and 175 chromosomally abnormal pregnancies, including 90 with trisomy 21, 28 with trisomy 18, 19 with trisomy 13, 28 with Turner...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Gestational Trophoblastic Disease Studies
Share to Pregnancy and preeclampsia studies
Share to Prenatal Screening and Diagnostics

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 19277983
DOI: 10.1002/uog.6331

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Maternal serum placental growth factor at 11–13 weeks in chromosomally abnormal pregnanciesPMID 19277983Read ↗

First trimester maternal serum placental growth factor in trisomy 21 pregnanciesSemantic proximity Read ↗

First trimester maternal serum pregnancy‐associated plasma protein A and pregnancy‐specific βl‐glycoprotein in fetal trisomiesSemantic proximity Read ↗

First‐trimester screening for trisomy 21 by free beta‐human chorionic gonadotropin and pregnancy‐associated plasma protein‐A: impact of maternal and pregnancy characteristicsSemantic proximity Read ↗

Maternal serum pregnancy‐associated plasma protein a and fetal nuchal translucency thickness for the prediction of fetal trisomies in early pregnancySemantic proximity Read ↗

Biochemical Screening for Fetal Trisomy 21: Pathophysiology of Maternal Serum Markers and Involvement of the PlacentaSemantic proximity Read ↗

Screening for trisomy 13 by fetal nuchal translucency and maternal serum free ?-hCG and PAPP-A at 10-14 weeks of gestationSemantic proximity Read ↗

Screening for triploidy by fetal nuchal translucency and maternal serum free ?-hCG and PAPP-A at 10-14 weeks of gestationSemantic proximity Read ↗

Study of first-trimester serum levels of β-hCG and PAPP-A as a screening test for fetal development of intrauterine growth restrictionSemantic proximity Read ↗

First‐trimester combined screening for trisomy 21 at 7–14 weeks' gestationSemantic proximity Read ↗

A screening program for trisomy 21 at 10–14 weeks using fetal nuchal translucency, maternal serum free β‐human chorionic gonadotropin and pregnancy‐associated plasma protein‐ASemantic proximity Read ↗

FIRST-TRIMESTER GROWTH PATTERNS OF ANEUPLOID FETUSESSemantic proximity Read ↗

A reassessment of biochemical marker distributions in trisomy 21‐affected and unaffected twin pregnancies in the first trimesterSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.